Surgery Partners (SGRY) is back in focus after reporting softer quarterly results, characterized by weak sales volumes, slower projected revenue growth, and high debt levels that increase financial risk and keep investor sentiment cautious.
See our latest analysis for Surgery Partners.
The share price slump has been sharp, with a 12.5% 30 day share price return and a 20.2% year to date share price return contributing to a 46.6% 1 year total shareholder return, which points to fading momentum as investors reassess risk after weaker results.
If you are weighing what to do next after this pullback, it could be a useful moment to look across healthcare and see which names are holding up better in AI enabled care, using the 37 healthcare AI stocks.
With Surgery Partners now trading at US$12.18 after a steep slide and carrying a value score of 5, plus a large gap to analyst targets and intrinsic estimates, is the pullback an opening or is the market already discounting future growth?
Most Popular Narrative: 52.2% Undervalued
Using a fair value of about $25.45 and a last close of $12.18, the most followed narrative sees Surgery Partners trading at a steep discount, built on detailed assumptions about future revenue, margins, and capital deployment.
Disciplined execution on M&A and portfolio optimization, including accretive acquisitions and potential asset sales or health system partnerships, should enhance margin expansion, accelerate deleveraging, and improve free cash flow conversion, supporting improvements in net margins and long-term earnings power.
Curious what kind of revenue trajectory and margin reset are baked into that fair value, and how much depends on future deal flow and divestitures timing? The full narrative spells out the growth path, the profitability swing, and the longer term earnings profile that need to line up for that valuation to hold.
Result: Fair Value of $25.45 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are pressure points to watch, including rising interest costs and slower than planned acquisitions, which could weaken earnings and challenge the undervaluation case.
Find out about the key risks to this Surgery Partners narrative.
Next Steps
Mixed messages on valuation, debt and growth can make this story feel complicated. Consider reviewing the full picture across 3 key rewards and 1 important warning sign while the details are still fresh.
Looking for more investment ideas?
If this update has you reassessing Surgery Partners, now is a smart time to widen your watchlist and compare it with other ideas surfaced by data driven screens.
- Spot potential value opportunities early by reviewing screener containing 25 high quality undiscovered gems before they gain wider attention.
- Prioritize resilience by checking stocks in the 67 resilient stocks with low risk scores that score well on downside protection.
- Target stronger balance sheets by using the solid balance sheet and fundamentals stocks screener (39 results) to see which companies pair financial stability with fundamentals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com